Skip to Content
Merck
All Photos(1)

Documents

B0470000

Benperidol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-{1-[4-(4-Fluorophenyl)-4-oxobutyl]-piperidin-4-yl}-1,3-dihydro-benzimidazol-2-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H24FN3O2
CAS Number:
2062-84-2
Molecular Weight:
381.44
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

benperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C22H24FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

InChI key

FEBOTPHFXYHVPL-UHFFFAOYSA-N

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Benperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S M Moerlein et al.
Nuclear medicine and biology, 22(6), 809-815 (1995-08-01)
[18F]Benperidol ([18F]BP), a positron-emitting analogue of the dopaminergic D2 antagonist benperidol, was evaluated as a radiopharmaceutical for use with positron emission tomography (PET). PET imaging of baboons after i.v. injection of [18F]BP indicated that the radiofluorinated ligand rapidly localized in
J Schröder et al.
Psychiatry research, 75(2), 115-123 (1997-11-14)
Recent studies have described a left lateralized striatal asymmetry of D2 dopamine receptors in male patients with schizophrenia. To replicate this finding and to explore its potential functional consequences, we investigated the D2 dopamine receptor system in 23 drug-naive patients
J Schröder et al.
Fortschritte der Neurologie-Psychiatrie, 68 Suppl 1, S42-S45 (2000-07-25)
Animal and post mortem studies indicate that neuroleptic therapy may induce D2-dopamine receptor upregulation in the basal ganglia. To address this phenomenon in a clinical study, we investigated the D2-dopamine receptor binding in 15 DSM-III-R schizophrenics in the drug-naive state
I Biryol et al.
Journal of pharmaceutical and biomedical analysis, 15(11), 1695-1701 (1997-07-01)
In this study two butyrophenones, droperidol and benperidol were voltammetrically investigated using platinum and specially activated glass carbon electrodes. The behaviours of the substance were investigated in various electrolyte solutions having different pH values and by different scan rates. As
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Carlos Schönfeldt-Lecuona et al.
Journal of clinical psychopharmacology, 24(1), 97-98 (2004-01-08)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service